Protagenic Therapeutics, Inc.
PTIX
$0.92
-$0.11-10.32%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.54% | -102.87% | 189.09% | 148.40% | 169.01% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.46% | -92.06% | 130.47% | 213.42% | 275.51% |
| Operating Income | 20.46% | 92.06% | -130.47% | -213.42% | -275.51% |
| Income Before Tax | 80.95% | 377.10% | 360.00% | -48.66% | -1,471.63% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 80.95% | 377.10% | 360.00% | -49.30% | -1,459.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 80.95% | 377.10% | 360.00% | -49.30% | -1,459.03% |
| EBIT | 20.46% | 92.06% | -130.47% | -213.42% | -275.51% |
| EBITDA | 20.31% | -- | -- | -- | -- |
| EPS Basic | 61.04% | 878.82% | 825.00% | -335.77% | -2,173.54% |
| Normalized Basic EPS | 50.45% | -69.89% | 824.97% | -333.33% | -1,675.34% |
| EPS Diluted | 61.04% | 878.82% | 825.00% | -335.77% | -2,173.54% |
| Normalized Diluted EPS | 50.45% | -69.89% | 824.97% | -333.33% | -1,675.34% |
| Average Basic Shares Outstanding | -51.09% | -64.42% | -64.14% | -65.72% | -31.40% |
| Average Diluted Shares Outstanding | -51.09% | -64.42% | -64.14% | -65.72% | -31.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |